Pacer Advisors
MDGL icon

Pacer Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Pacer Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53K Buy
+98
New +$50.2K ﹤0.01% 2024
2024
Q3 		– Sell
-207
Closed -$58K – 2636
2024
Q2 		$58K Buy
207
+37
+22% +$8.81K ﹤0.01% 3043
2024
Q1 		$45.4K Buy
+170
New +$40.1K ﹤0.01% 3207
2021
Q2 		– Sell
-656
Closed -$77K – 1491
2021
Q1 		$77K Sell
656
-330
-33% -$38.5K ﹤0.01% 1333
2020
Q4 		$110K Buy
986
+150
+18% +$18.3K ﹤0.01% 1354
2020
Q3 		$99K Buy
+836
New +$90.8K ﹤0.01% 1250
2018
Q4 		– Sell
-1,078
Closed -$231K – 841
2018
Q3 		$231K Buy
+1,078
New +$271K 0.01% 1002

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pacer Advisors's MDGL Position: Q2 2026 in Review

Pacer Advisors opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 98 shares worth $53K. The stake represents ﹤0.01% of the portfolio and ranks #2024 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in MDGL as recently as Q2 2024.

Pacer Advisors first reported a position in MDGL in Q3 2018 and has held it in 7 quarters since. The position peaked at $231K in Q3 2018. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Pacer Advisors held 98 shares of Madrigal Pharmaceuticals worth $53K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Pacer Advisors position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2024 holding.
  • Pacer Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2018 and has held it in 7 quarters since.
  • Pacer Advisors's Madrigal Pharmaceuticals position peaked at $231K in Q3 2018.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.